Clinical trialNCT06864403RecruitingPhase 4Interventional

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

SponsorUniversity of North Carolina, Chapel HillEnrollment25Pouch, IlealPouches, IleoanalPouchitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to learn if mirikizumab works to treat pouch disorders in adults. The main questions it aims to answer are: Does mirikizumab reduce symptoms of pouch disorders Participants will: Take mirikizumab every 4 weeks for one year Visit the clinic once every month for two months and at the end of the study Keep a diary of their symptoms

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Edward Barnes, MD, MPH
University of North Carolina
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucla Vatche & Tamar Manoukian Division of Digestive Diseases
Los Angeles, California, United States
Gaurav Syal, MD
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Laura Raffals
Recruiting
Nyu Langone Health
New York, New York, United States
Shannon Chang, MD, MBA
Recruiting
University of North Carolina
Chapel Hill, North Carolina, United States
Edward Barnes, MD, MPH
Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania, United States
Gursimran Kochhar
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mirikizumab - IntravenousMirikizumab - Subcutaneous

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Aug 2025
Primary completion: 30 Apr 2027
Completion: 30 Apr 2027
Last update posted: 30 Jan 2026
Registered enrollment: 25
Registry id: NCT06864403

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.